107618-21-3

Basic information

• Product Name: 4-(2-aMino-4-fluoro-phenylaMino)-piperidine-1-carboxylic acid ethyl ester
• Synonyms: 4-(2-aMino-4-fluoro-phenylaMino)-piperidine-1-carboxylic acid ethyl ester;1-PIPERIDINECARBOXYLIC ACID, 4-[(2-AMINO-4-FLUOROPHENYL)AMINO]-, ETHYL ESTER
• CAS NO: 107618-21-3
• Molecular Weight: 281.33
• Mol File: 107618-21-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-(2-aMino-4-fluoro-phenylaMino)-piperidine-1-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-aMino-4-fluoro-phenylaMino)-piperidine-1-carboxylic acid ethyl ester(107618-21-3)
• EPA Substance Registry System: 4-(2-aMino-4-fluoro-phenylaMino)-piperidine-1-carboxylic acid ethyl ester(107618-21-3)

Safety Data

• Hazardous Substances Data: 107618-21-3(Hazardous Substances Data)

Upstream product

• 345-17-5 1-chloro-4-fluoro-2-nitrobenzene 
• 107618-14-4 4-(4-fluoro-2-nitro-phenylamino)-piperidine-1-carboxylic acid ethyl ester 
• 7440-06-4 platinum 
• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 

Downstream Products

• 107618-33-7 4-(5-fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid ethyl ester 
• 618900-33-7 C₁₆H₂₀FN₃O₂S 
• 1469924-47-7 C₂₁H₂₀F₃N₃O₃ 
• 1469924-46-6 C₂₁H₂₀F₃N₃O₃ 
• 1469924-45-5 C₂₂H₃₀FN₃O₃ 
• 1469924-60-4 C₁₈H₁₆F₃N₃O 
• 1469924-59-1 C₁₈H₁₆F₃N₃O 
• 1469924-58-0 C₁₉H₂₆FN₃O 
• 1469924-78-4 C₄₀H₄₇F₃N₆O₆ 
• 1469924-77-3 C₄₀H₄₇F₃N₆O₆ 
• 1469924-76-2 C₄₁H₅₇FN₆O₆ 
• 633311-66-7 C₃₀H₃₁F₃N₆O₂ 
• 633311-57-6 C₃₀H₃₁F₃N₆O₂ 
• 633310-95-9 C₃₁H₄₁FN₆O₂ 

Relevant articles and documents

Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties

This Letter describes the first account of the synthesis and SAR, developed through an iterative analogue library approach, of analogues of the highly selective M1 allosteric agonist TBPB. With slight structural changes, mAChR selectivity was maintained, but the degree of partial M1 agonism varied considerably.

Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine

In our continuing effort to identify CGRP receptor antagonists for the acute treatment of migraine, we have undertaken a study to evaluate alternative 4-substituted piperidines to the lead dihydroquinazolinone 1. In this regard, we have identified the piperidinyl-azabenzimidazolone and phenylimidazolinone structures which, when incorporated into the benzodiazepine core, afford potent CGRP receptor antagonists (e.g., 18 and 29). These studies produced a potent analog (18) which overcomes the instability issues associated with the lead structure 1. A general pharmacophore for the 4-substituted piperidine component of these CGRP receptor antagonists is also presented.

Piperidines

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides substituted piperidines, and compositions containing these compounds. Also provided are methods using the compounds of the invention for the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.